cecropin/neoplasms

This invention pertains to transformed mammalian cells capable of expressing the lytic peptide cecropin B, and uses for such cells. INTRODUCTION Few effective treatments exist for either acute or chronic intracellular bacterial, protozoal, or viral diseases of animals or humans. In many such

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method of combatting mammalian neoplasias, including specifically female mammalian neoplasias, and to non-naturally lytic peptides and their use in such method. 2. Description of Related Art Naturally occurring

FIELD OF THE INVENTION The present invention relates to lytic peptides, their use in methods for inhibiting eucaryotic pathogens, cancer cells and intracellularly infected cells, and their use in methods for stimulating the proliferation of fibroblasts and lymphocytes. More particularly, this

This invention pertains to transformed animals and animal cells capable of expressing exogenous lytic peptides; and to genes in eukaryotic cells controlled by exogenous promoters that are responsive to inducers of acute phase proteins; and to transposon-based transformation vectors. Lytic

This invention pertains to transgenic fish and transgenic fish cells capable of expressing exogenous lytic peptides. Lytic Peptides Few effective treatments exist for either acute or chronic intracellular bacterial, protozoal, or viral diseases of animals, including humans. In many such infections,

FIELD OF THE INVENTION The present invention relates to lytic peptides, their use in methods for inhibiting eucaryotic pathogens, cancer cells and intracellularly infected cells, and their use in methods for stimulating the proliferation of fibroblasts and lymphocytes. More particularly, this